New data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from June 8-10 in Chicago, Illinois, built on previously published top-line results comparing upadacitinib to dupilumab by demonstrating superiority for all ranked secondary endpoints at varying response levels and time points, including complete skin clearance and rapid resolution of itching in patients with severe itch.

“Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Results of an Open-label, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up)” was presented by Jonathan I. Silverberg, MD, PhD, MPH, and colleagues.

New highlights included a significantly higher proportion of patients treated with upadacitinib achieving:

• complete skin clearance (EASI 100) at week 16 [(14.8% vs 5.6%, p<0.0001)];
• rapid onset of itch relief (WP-NRS 0/1) as early as after 2 weeks [(7.7% vs 1.3%, p<0.0001)] in addition to rapid skin clearance (EASI 90) achieved at week 4 for 23.8% of upadacitinib patients vs 9.7% of dupilumab patients;
• and improvement in itching also among those patients with severe itch at baseline (WP-NRS ≥4) [(54.7% vs 38.1%, p<0.0001)].

No new safety signals beyond the known safety profile of upadacitinib and dupilumab were identified during the 16-week period.